vs
Amphastar Pharmaceuticals, Inc.（AMPH）とShimmick Corp（SHIM）の財務データ比較。上の社名をクリックして会社を切り替えられます
Amphastar Pharmaceuticals, Inc.の直近四半期売上が大きい（$183.1M vs $141.9M、Shimmick Corpの約1.3倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs -3.1%、差は16.4%）。Amphastar Pharmaceuticals, Inc.の直近四半期フリーキャッシュフローが多い（$24.6M vs $-28.7M）。過去8四半期でAmphastar Pharmaceuticals, Inc.の売上複合成長率が高い（3.2% vs -10.1%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
Shimmick Corpは米国を拠点とする重土木建設会社で、上下水道施設、交通インフラ、ダム工事、環境修復事業などの公共インフラの建設・改修を専門としています。主な顧客は北米の連邦・州・地方自治体で、大規模で複雑な建設プロジェクトを手がけています。
AMPH vs SHIM — 直接比較
損益計算書 — Q4 FY2025 vs Q3 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $141.9M |
| 純利益 | $24.4M | $-4.4M |
| 粗利率 | 46.8% | 7.6% |
| 営業利益率 | 19.4% | -2.2% |
| 純利益率 | 13.3% | -3.1% |
| 売上前年比 | -1.8% | — |
| 純利益前年比 | -35.7% | — |
| EPS（希薄化後） | $0.51 | $-0.12 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $141.9M | ||
| Q3 25 | $191.8M | $128.4M | ||
| Q2 25 | $174.4M | $122.1M | ||
| Q1 25 | $170.5M | $103.6M | ||
| Q4 24 | $186.5M | — | ||
| Q3 24 | $191.2M | $166.0M | ||
| Q2 24 | $182.4M | $90.6M | ||
| Q1 24 | $171.8M | $120.0M |
| Q4 25 | $24.4M | $-4.4M | ||
| Q3 25 | $17.4M | $-8.5M | ||
| Q2 25 | $31.0M | $-9.8M | ||
| Q1 25 | $25.3M | $-38.5M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $-1.6M | ||
| Q2 24 | $37.9M | $-51.4M | ||
| Q1 24 | $43.2M | $-33.3M |
| Q4 25 | 46.8% | 7.6% | ||
| Q3 25 | 51.4% | 6.3% | ||
| Q2 25 | 49.6% | 3.8% | ||
| Q1 25 | 50.0% | -20.1% | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | 7.3% | ||
| Q2 24 | 52.2% | -34.4% | ||
| Q1 24 | 52.4% | -13.2% |
| Q4 25 | 19.4% | -2.2% | ||
| Q3 25 | 13.2% | -5.5% | ||
| Q2 25 | 24.2% | -7.3% | ||
| Q1 25 | 21.9% | -39.3% | ||
| Q4 24 | 24.2% | — | ||
| Q3 24 | 29.8% | 0.7% | ||
| Q2 24 | 30.3% | -53.0% | ||
| Q1 24 | 27.9% | -26.5% |
| Q4 25 | 13.3% | -3.1% | ||
| Q3 25 | 9.0% | -6.6% | ||
| Q2 25 | 17.8% | -8.0% | ||
| Q1 25 | 14.8% | -37.1% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | -0.9% | ||
| Q2 24 | 20.8% | -56.7% | ||
| Q1 24 | 25.1% | -27.8% |
| Q4 25 | $0.51 | $-0.12 | ||
| Q3 25 | $0.37 | $-0.25 | ||
| Q2 25 | $0.64 | $-0.28 | ||
| Q1 25 | $0.51 | $-0.92 | ||
| Q4 24 | $0.74 | — | ||
| Q3 24 | $0.78 | $-0.05 | ||
| Q2 24 | $0.73 | $-1.83 | ||
| Q1 24 | $0.81 | $-1.30 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $17.6M |
| 総負債低いほど良い | $608.7M | $57.5M |
| 株主資本純資産 | $788.8M | $-52.7M |
| 総資産 | $1.6B | $218.5M |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $17.6M | ||
| Q3 25 | $276.2M | $21.4M | ||
| Q2 25 | $231.8M | $16.3M | ||
| Q1 25 | $236.9M | $33.7M | ||
| Q4 24 | $221.6M | — | ||
| Q3 24 | $250.5M | $26.0M | ||
| Q2 24 | $217.8M | $22.4M | ||
| Q1 24 | $289.6M | $27.3M |
| Q4 25 | $608.7M | $57.5M | ||
| Q3 25 | $608.6M | $36.4M | ||
| Q2 25 | $607.7M | $31.4M | ||
| Q1 25 | $603.9M | $9.5M | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | $39.9M | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | $31.5M |
| Q4 25 | $788.8M | $-52.7M | ||
| Q3 25 | $776.7M | $-49.5M | ||
| Q2 25 | $757.5M | $-42.6M | ||
| Q1 25 | $751.3M | $-34.7M | ||
| Q4 24 | $732.3M | — | ||
| Q3 24 | $727.7M | $973.0K | ||
| Q2 24 | $713.3M | $436.0K | ||
| Q1 24 | $672.4M | $38.1M |
| Q4 25 | $1.6B | $218.5M | ||
| Q3 25 | $1.7B | $203.0M | ||
| Q2 25 | $1.6B | $227.7M | ||
| Q1 25 | $1.6B | $233.9M | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | $1.5B | $346.7M | ||
| Q2 24 | $1.5B | $344.5M | ||
| Q1 24 | $1.6B | $378.0M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | 41.01× | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | 0.83× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $-23.7M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $-28.7M |
| FCFマージンFCF / 売上 | 13.4% | -20.2% |
| 設備投資強度設備投資 / 売上 | 4.5% | 3.5% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | — |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $-27.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $-23.7M | ||
| Q3 25 | $52.6M | $-3.8M | ||
| Q2 25 | $35.6M | $-38.2M | ||
| Q1 25 | $35.1M | $44.9M | ||
| Q4 24 | $29.0M | — | ||
| Q3 24 | $60.0M | $12.7M | ||
| Q2 24 | $69.1M | $-43.9M | ||
| Q1 24 | $55.3M | $-35.0M |
| Q4 25 | $24.6M | $-28.7M | ||
| Q3 25 | $47.2M | $-4.2M | ||
| Q2 25 | $25.0M | $-38.7M | ||
| Q1 25 | $24.4M | $44.4M | ||
| Q4 24 | $16.6M | — | ||
| Q3 24 | $46.2M | $10.3M | ||
| Q2 24 | $63.1M | $-46.8M | ||
| Q1 24 | $46.5M | $-39.6M |
| Q4 25 | 13.4% | -20.2% | ||
| Q3 25 | 24.6% | -3.2% | ||
| Q2 25 | 14.3% | -31.7% | ||
| Q1 25 | 14.3% | 42.9% | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 24.1% | 6.2% | ||
| Q2 24 | 34.6% | -51.7% | ||
| Q1 24 | 27.1% | -33.0% |
| Q4 25 | 4.5% | 3.5% | ||
| Q3 25 | 2.8% | 0.3% | ||
| Q2 25 | 6.1% | 0.4% | ||
| Q1 25 | 6.3% | 0.5% | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 7.2% | 1.4% | ||
| Q2 24 | 3.3% | 3.3% | ||
| Q1 24 | 5.1% | 3.8% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
SHIM
| Shimmick Projects | $106.8M | 75% |
| Non Core Projects | $35.1M | 25% |
